52 results about "Non metastatic" patented technology

Disclosed herein are methods of treating benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating a subject at risk of developing benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating or preventing recurrence of a tumor using an anti-VEGF-specific antagonist as well as use of VEGF-specific antagonists in neoadjuvant and adjuvant cancer therapy.

The invention relates to a methylated biomarker or a combination thereof for detecting gastric cancer lymph node metastasis and non-metastasis and application of the methylated biomarker. The methylated biomarker is selected from at least one of chr12: 42873140, chr8: 81789921, chr8: 81811441 and chr8: 16884489. According to the invention, the appropriate DNA methylation biomarker is screened and used for detecting gastric cancer lymph node metastasis and non-metastasis, and the DNA methylation biomarker can achieve the purpose of accurate prediction. The novel DNA methylation marker developed by the invention can be used for identifying whether the lymph node metastasis of the early gastric cancer occurs or not, can be used for assisting clinical accurate diagnosis and guiding treatment, and also can be used for technical research in laboratories.

The inventors of the present invention have surprisingly discovered that EGFR expression in nonmetastatic breast cancer patients with CK-negative CTCs could induce EMT process. A simultaneous detection of both EGFR and EMT markers (VIM and Slug) in CTCs might improve prognostic or predictive information in patients with operable breast cancer.

The invention provides an HNC (Head and Neck Cancer) prognosis biomarker based on a lymph node microbial flora and application of the HNC prognosis biomarker, and belongs to the technical field of disease prognosis and molecular biology. According to the invention, the 16S ribosomal RNA gene of the lymph node microbial flora of an HNC patient is subjected to high-throughput sequencing, so that it is proved that different species exist in flora species of metastatic lymph nodes and non-metastatic lymph nodes in the HNC patient; furthermore, through a microbial flora symbiotic relationship network, it is found that the flora interrelation between the species of the metastatic lymph node and the species of the non-metastatic lymph node of the HNC patient is also different at the genus level; the result discovers the characteristics of the microbiome of the metastatic lymph node and the non-metastatic lymph node of the HNC patient for the first time; and meanwhile, it is known by analysis that the flora difference characteristics (diversity index values and relative abundance of different species) have a good prediction effect on the lifetime (total lifetime and three-year lifetime) of the HNC patient, so that the invention has a good practical application value.

Among the genes identified, in a comparison of the global gene expression profile of metastatic colorectal cancer to that of primary cancers, benign colorectal tumors, and normal colorectal epithelium, the PRL-3 protein tyrosine phosphatase gene was of particular interest. It was expressed at high levels in each of 18 cancer metastases studied but at lower levels in non-metastatic tumors and normal colorectal epithelium. In three of twelve metastases examined, multiple copies of the PRL-3 gene were found within a small amplicon located at chromosome 8q24.3. These data suggest that the PRL-3 gene is important for colorectal cancer metastasis and provides a new therapeutic target for these intractable lesions.

The invention relates to the technical field of biology, and especially relates to applications of CTx to preparation of medicaments for diagnosing colorectal cancer, wherein CTx is a fragment at the carboxyl telopeptide of an extracellular matrix component type I collagen. The invention provides applications of CTx to prepare and screen medicaments for diagnosing colorectal cancer and screen medicaments for treating colorectal cancer. Colorectal cancer tissues and serum clinic specimens are selected for researching the clinic value of type I collagen on generation, development, staging prognosis and the like of colorectal cancer. Through a large number of experiments, inventors of the invention discover that the expression level change of CTx in serums of colorectal cancer patients at different stages is in positive correlation with pathology staging, and compared with conventional alimentary canal tumour oncofetal antigens, CTx is capable of better differencing the metastatic colorectal cancer patients and the non-metastatic colorectal cancer patients. Additionally, the inventors also discover that CTx is correlated with 3-year tumor-free survival of the colorectal cancer patients, and the high expression of CTx indicates poor tumor-free survival and prognosis of the colorectal cancer patients.

The invention discloses a medicament for treating colon cancer and a preparation method thereof. The medicament is prepared from medicinal active ingredients and pharmaceutic adjuvant, wherein the medicinal active ingredients comprise 3 beta-hydroxyl-28-deletion-12,17(18)-diene ursane. The preparation method comprises the following steps of: (1) adding methanol or ethanol into crushed charred sanguisorba root serving as a medicinal raw material, filtering the mixture, concentrating filtrate under normal pressure or reduced pressure to obtain extractum liquidum; (2) dispersing the extractum liquidum obtained by the step (1) with water, and extracting with chloroform to obtain extractum; (3) carrying out silicagel column chromatographic separation on the extractum obtained by the step (2) recovering a solvent, placing the solvent to separate white powder out, filtering the mixture to obtain the 3 beta-hydroxyl-28-deletion-12,17(18)-diene ursane; and (4) preparing the medicament from 20 to 90 weight percent of the 3 beta-hydroxyl-28-deletion-12,17(18)-diene ursane, and the balance of the pharmaceutic adjuvant by a conventional preparation method. The medicament mainly treats non-metastatic symptoms of the colon cancer, has no toxic or side effects, and is used by matching postoperative chemotherapy so as to relieve pain of patients.

The invention relates to 21 microRNA markers for discriminating metastatic and non-metastatic squamous cell lung carcinoma. More specifically, the invention relates to a class of microRNA markers for discriminating metastatic and non-metastatic squamous cell lung carcinoma. It has been proved by examination that, the specific microRNA markers can effectively discriminate metastatic and non-metastatic squamous cell lung carcinoma tissue. The invention also relates to a chip and a test kit for detecting the microRNA markers.

A diagnostic device includes a microscope configured to obtain image data on a plurality of cells and a computing device. The computing device is configured to receive the image data, identify at least a portion of each of the plurality of cells based on the received image data, determine at least one of a value of a morphological parameter for each identified at least a portion of the plurality of cells or a relative organization among the identified at least a portion of the plurality of cells, and calculate statistics for the plurality of cells based on the at least one of the determined values of the morphological parameter or the determined relative organization, the statistics including information suitable for distinguishing metastatic cells from non-metastatic cells. The diagnostic device further includes an output device configured to output the statistics for diagnosis.

The invention relates to a novel application of mir-3613 and mature miRNA thereof. Based upon transcriptome sequencing on samples of metastatic esophageal squamous carcinoma tissues, non-metastatic esophageal squamous carcinoma tissues and para-carcinoma tissues, as well as analysis which is implemented in accordance with a bio-informatics method, some molecular markers related to esophageal squamous carcinoma are discovered, and the expression quantity of miR-3613-5p in the carcinoma tissues is higher than that of miR-3613-5p in the para-carcinoma tissues; and furthermore, a fluorescent quantitative PCR experimental result is consistent with a high-throughput sequencing result. The invention offers potential molecular markers for the precise diagnosis of the esophageal squamous carcinoma in the clinical field; and an important practical application value is achieved.

The present invention relates to the identification and diagnostic use of biomarkers in primary colorectal cancer tumors whose activation level are predictive of the likelihood of the onset of metastatic disease. These biomarkers may be used to determine the suitability of a patient for aggressive and / or targeted treatments. Kits and compositions of the invention are also provided.